Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Hodgkin Disease × avelumab × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 10 Carcinoma, Non-Small-Cell Lung 7 Ovarian Neoplasms 6 Carcinoma, Transitional Cell 6 Squamous Cell Carcinoma of Head and Neck 5 Neoplasm Metastasis 5 Carcinoma, Renal Cell 5 Breast Neoplasms 4 Triple Negative Breast Neoplasms 3 Recurrence 3 Melanoma 3 Colorectal Neoplasms 3 Urinary Bladder Neoplasms 2 Sarcoma 2 Lymphoma, Follicular 2 Lymphoma 2 Central Nervous System Neoplasms 2 Uveal Melanoma 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Solid Tumors 1 Skin Neoplasms 1 Sezary Syndrome 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Mycosis Fungoides 1 Metastatic Urothelial Cell Cancer 1 Metastatic Solid Tumors 1

Interventions

Cyclophosphamide 24 fludarabine phosphate 22 Filgrastim 15 Gemcitabine 14 fludarabine 13 Rituximab 13 Brentuximab Vedotin 13 Peripheral Blood Stem Cell Transplantation 12 Whole-Body Irradiation 11 Vorinostat 11 Tacrolimus 11 Bortezomib 10 Mycophenolic Acid 9 Melphalan 9 Etoposide 9 Busulfan 9 Sirolimus 8 Lenalidomide 8 Azacitidine 8 Nivolumab 7 Dexamethasone 7 pembrolizumab 6 Radiotherapy 6 Cytarabine 6 Antilymphocyte Serum 6 romidepsin 5 aldesleukin 5 Panobinostat 5 Leucovorin 5 Doxorubicin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02603419 2020-04-24

JAVELIN HODGKINS

Pfizer

Phase 1 Terminated

34 enrolled 43 charts

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡